Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 8/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18129430 | 0.92 | TDP2 (0.36) | PDK2CA1CA2CA7CA9 | |
| SCHEMBL14690993 | 0.78 | TDP2 (0.36) | PDK2CA1CA2CA7CA9 | |
| SCHEMBL8749990 | 0.73 | RXRA (0.52) | RECQLESR1 | |
| SCHEMBL29344902 | 0.72 | PRSS1 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL482663 | 0.71 | ALDH1A1 (0.44) | HPGDL3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL3596705 | 0.70 | MAPT (0.47) | HPGDMAPTALDH1A1CYP2C19NPSR1 | |
| SCHEMBL14456161 | 0.69 | CA1 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2630547 | 0.69 | GAA (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16891316 | 0.68 | PDK2 (0.57) | PDK2HPGDL3MBTL1MAPTALDH1A1 | |
| SCHEMBL12682917 | 0.68 | ALDH1A1 (0.32) | TSHRL3MBTL1MAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512108-B2 | 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-12-06 | — | — | US | disclosed |
| US-9512108-B2 | 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-12-06 | — | — | US | disclosed |
| US-9512108-B2 | 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-12-06 | — | — | US | disclosed |
| EP-3091010-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| EP-3091010-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| US-20160297804-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-10-13 | — | — | US | disclosed |
| US-20160297804-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-10-13 | — | — | US | disclosed |
| US-20160297804-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-10-13 | — | — | US | disclosed |
| WO-2015101215-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | 南京圣和药业股份有限公司 | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297804-A1 | 9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF | SLC10A1, CYP2C9, UGT1A9 | PDK2 3770/4885CA12 947/4885CA1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.